Webinar IRISCAT- Dr. Scott Berry "The Scientific Innovations of the REMAP-CAP Platform Trial"

 
  Activitat Online —
30/06/2021
30/06/2021 -- From 16:00h to 17:00h
Organize :
Vall d'Hebron Institut de Recerca (VHIR)
Modality: In-person
Share it:

The COVID-19 pandemic created a unique scientific dilemma for the science of understanding what therapies are beneficial, and whom do they benefit. The existing clinical trial science is way to slow and inefficient to get reliable answers in time to impact the global pandemic.  Platform trials have provided an incredible response to the pandemic providing much needed, reliable, results on the therapeutic treatments for COVID-19.  While the platforms have been incredibly successful in response to the pandemic they have also advanced clinical trial science.  In this talk I will focus on the REMAP-CAP platform trial, and the scientific advances within the trial.  These innovations include continual adaptive analyses, multifactorial randomization to patients, flexibility to add and subtract therapies as science evolves, response adaptive randomization, modeling of heterogeneous treatment effects, and applications of Bayesian statistics.

Bio: Scott Berry is President and a Senior Statistical Scientist at Berry Consultants, LLC.  Since 2000, he has been involved in the design of hundreds of Bayesian adaptive clinical trials of pharmaceuticals and medical devices and has become an opinion leader in the field of Bayesian adaptive clinical trials.  Some of these trials have been groundbreaking trial designs, setting new standards for innovation and flexibility in trial design.  These include the trials supporting the first fully Bayesian approval by CDER of the United States FDA (Pravastatin-Aspirin combination) and the statistical design for Time Magazine’s #2 Medical Breakthrough of 2007 (Veridex’s GeneSearch BLN Assay), and an adaptive phase II/III seamless trial for Dulaglutide leading to FDA approval in September 2014.  Recently he has been involved in the design of multiple adaptive platform trials for the treatment of COVID-19, including the REMAP-CAP COVID-19 platform trial, ACTIV-4a, and the mpRCT AARC.

He earned his PhD in statistics from Carnegie Mellon University and was an Assistant Professor at Texas A&M University before co-founding Berry Consultants in 2000. He is adjunct faculty in the Department of Biostatistics at the University of Kansas Medical Center.  Dr. Berry was elected as a Fellow of the American Statistical Association in 2013.

Inscriu-t'hi aquí

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.